↓ Skip to main content

A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Overview of attention for article published in Clinical Cancer Research, February 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

blogs
1 blog
twitter
8 tweeters

Readers on

mendeley
3 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Published in
Clinical Cancer Research, February 2022
DOI 10.1158/1078-0432.ccr-21-4302
Pubmed ID
Authors

Ivan de Kouchkovsky, Arpit Rao, Benedito A. Carneiro, Li Zhang, Catriona Lewis, Audrey Phone, Eric J. Small, Terence Friedlander, Lawrence Fong, Pamela L. Paris, Charles J. Ryan, Russell Z. Szmulewitz, Rahul Aggarwal

Abstract

Ribociclib, a CDK4/6 inhibitor, demonstrates pre-clinical anti-tumor activity in combination with taxanes. We evaluated the safety and efficacy of ribociclib plus docetaxel in a phase Ib/II study in metastatic castration-resistant prostate cancer (mCRPC). Patients had chemotherapy-naive mCRPC with progression on {greater than or equal to} 1 androgen receptor signaling inhibitor (ARSI). The phase II primary endpoint was 6-month radiographic progression-free survival (rPFS) rate, with an alternative hypothesis of 55% versus 35% historical control. Circulating tumor cells (CTC) were collected at baseline and genomically profiled. Forty-three patients were enrolled (N = 30 in Phase II). Two dose-limiting toxicities were observed (Grade 4 neutropenia and febrile neutropenia). The recommended phase 2 dose (RP2D) and schedule was docetaxel 60 mg/m2 every 21 days plus ribociclib 400 mg/day on days 1-4 and 8-15 with filgrastim on days 5-7. At the RP2D, neutropenia was the most common grade {greater than or equal to} 3 adverse event (37%); however, no cases of febrile neutropenia were observed. The primary endpoint was met; the 6-month rPFS rate was 65.8% (95% CI: 50.6% - 85.5%; p = 0.005) and median rPFS was 8.1 months (95% CI: 6.0 - 10.0 months). 32% of evaluable patients achieved a PSA50 response. Non-amplified <em>MYC </em>in baseline CTCs was associated with longer rPFS (p = 0.052). The combination of intermittent ribociclib plus every 3-week docetaxel demonstrated acceptable toxicity and encouraging efficacy in ARSI-pretreated mCRPC. Genomic profiling of CTCs may enrich for those most likely to derive benefit. Further evaluation in a randomized clinical trial is warranted.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 3 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 33%
Researcher 1 33%
Unknown 1 33%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 1 33%
Medicine and Dentistry 1 33%
Unknown 1 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2022.
All research outputs
#2,543,655
of 21,423,731 outputs
Outputs from Clinical Cancer Research
#2,195
of 12,197 outputs
Outputs of similar age
#53,313
of 335,112 outputs
Outputs of similar age from Clinical Cancer Research
#57
of 129 outputs
Altmetric has tracked 21,423,731 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,197 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 335,112 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 129 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.